Stay updated on IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial page.

Latest updates to the IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe NIH grant/contract note was added to the study identifiers, and the page revision tag was updated from v3.6.5 to v3.6.6.SummaryDifference0.1%

- Check22 days agoNo Change Detected
- Check36 days agoChange DetectedThe study page now shows an error message and a minimal HTML structure, indicating the record is currently unavailable.SummaryDifference18%

- Check51 days agoChange DetectedThe page now shows Revision: v3.6.4, replacing the previous Revision: v3.6.3. This indicates a new site release is in effect, without altering any study content or data on the page.SummaryDifference0.0%

- Check72 days agoChange DetectedThe page's revision label was updated from v3.6.2 to v3.6.3, signaling a new version of the page content.SummaryDifference0.0%

- Check80 days agoChange DetectedThe page now displays Revision: v3.6.2, replacing the previous Revision: v3.6.0. This represents a new build of the page without altering the study data or content.SummaryDifference0.0%

- Check94 days agoChange DetectedRecruitment status updated to 'No longer looking for participants'. New help sections were added to guide users on reading the study record and joining the study, and the Intervention/Treatment label was updated.SummaryDifference0.4%

Stay in the know with updates to IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial page.